Loading ....
Contact us to order
Tel
+1 866.986.9598
Applied Biological Materials (abm) Inc.
view supplier detailsCredit card payments now incur a 3% fee.
Applied Biological Materials (abm) Inc.
view supplier detailsCredit card payments now incur a 3% fee.
| Mfr.No. | Z101437 |
| Description | EPO is predominantly synthesized and secreted by tubular and juxtatubular capillary, endothelial, and interstitial cells of the kidney. Approximately 10-15% of the total amount of EPO comes from extrarenal sources and is predominantly produced by hepatocytes and Kupffer cells of the liver. Approximately 40% of the molecular mass of EPO is due to its glycosylation. Glycosylation is an important factor determining the pharmacokinetic behaviour of EPO in vivo. Non-glycosylated Epo has an extremely short biological half life. Recombinant Human EPO is a glycosylated protein that runs at approximately 35 kDa owing to its glycosylation. |
| Alternative Names | Erythropoietin Recombinant Human Erythropoietin-Alpha (EPO) |
| Appearance | Lyophilized Powder |
| Reconstitution | A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers. |
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS (pH 7) |
| Molecular Weight | 20.0 kDa |
| Quantity | 500 µg |
| Source | HEK293 |
| Usage | For research use only. Not for diagnostic or therapeutic use. |
| Accession Number | P01588 |
| Endotoxin Level | <1.0 EU/μg of recombinant protein as determined by the LAL method |
| Bioactivity | Activity was determined by the dose-dependent proliferation assay using a factor-dependent human erythroleukemic cell line TF-1 and was found to be less than 0.2ng/ml, 
|
| Gel Image | 
|
